10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference

PLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m.

PRNewsWire • Feb 19, 2026

Torex Gold Resources Inc. (TXG:CA) Q4 2025 Earnings Call Transcript

Torex Gold Resources Inc. (TXG:CA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 19, 2026

10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript

10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 14, 2026

10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026.

PRNewsWire • Feb 12, 2026

10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.4 per share a year ago.

Zacks Investment Research • Feb 12, 2026

Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Feb 13, 2026

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 5, 2026

PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology

Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel precision medicine PLEASANTON, Calif., Feb. 4, 2026 /PRNewswire/ --  10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that PharosAI , a research consortium uniting four leading UK institutions, will use the 10x Genomics Xenium spatial platform to build one of the world's most comprehensive multimodal cancer datasets and pair them with advanced AI models and analytical capabilities.

PRNewsWire • Feb 4, 2026

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026.

PRNewsWire • Jan 22, 2026

3 Medical Info Systems Stocks to Gain From Digitization Despite Industry Woes

Medical Info Systems rides AI and telehealth tailwinds, lifting DOCS, TXG and OMCL, but cyber risks and industry underperformance keep optimism in check.

Zacks Investment Research • Jan 21, 2026